SCHEMBL10202077

SCHEMBL10202077

C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H](C)N1CC(C)(C)C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.51
USP2 O75604 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GPR119 Q8TDV5 2/20 0.40
NAMPT P43490 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
HPGD P15428 1/20 0.40
RECQL P46063 1/20 0.38
EPHX1 P07099 1/20 0.38
DDB1 Q16531 1/20 0.37
CRBN Q96SW2 1/20 0.37
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37
RORC P51449 1/20 0.36
SETD7 Q8WTS6 1/20 0.36
EPHX2 P34913 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15871714 0.86 NR1H2 (0.51) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL20680170 0.86 NR1H2 (0.51) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL30338313 0.83 NR1H2 (0.49) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL30778455 0.83 NR1H2 (0.49) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL10264379 0.83 NR1H2 (0.49) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL334402 0.83 NR1H2 (0.53) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL10220898 0.83 NR1H2 (0.53) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL30115827 0.83 NR1H2 (0.49) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL7466688 0.82 NR1H2 (0.48) NR1H2USP2SMN1; SMN2GPR119NAMPT
SCHEMBL16246175 0.82 NR1H2 (0.48) NR1H2USP2SMN1; SMN2GPR119NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9993554-B2 Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2018-06-12 US disclosed
US-9993554-B2 Use of P13K Inhibitors for the Treatment of Obesity, Steatosis and ageing CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2018-06-12 US disclosed
US-8778935-B2 Imidazopyrazines for use as kinase inhibitors CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2014-07-15 US disclosed
US-20140154232-A1 Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2014-06-05 US disclosed
US-20120083492-A1 IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS (CNIO) (ES) 2012-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140154232-A1 Use of Pl3K Inhibitors for the Treatment of Obesity, Steatosis and Ageing PLIN1, PCK2, PLIN3 NR1H2 904/4885USP2 1248/4885SMN1; SMN2 4588/4885
US-20120083492-A1 IMIDAZOPYRAZINES FOR USE AS KINASE INHIBITORS MTOR, PIK3CA, PI4KA NR1H2 827/4885USP2 3475/4885SMN1; SMN2 3221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.